Insights

Growing Sleep Tech Modius Sleep, launched October 2024, targets chronic insomnia and is FDA-cleared non-invasive neurostimulation. This presents a recurring sales opportunity with sleep clinics, hospitals, VA programs, and physician networks seeking non-pharmacological insomnia treatments.

Health Tech Funding Recent funding rounds totaling over $8 million with a £6 million round indicate investor confidence and potential for scale. Leverage this momentum to engage strategic investors, venture-backed healthcare distributors, and potential co-development partners.

Global Expansion Readiness Headquartered in Belfast with global ambitions and recognition at industry events (CES, SleepTech awards) suggests readiness to partner with international distributors, healthcare systems, and private clinics in multiple regions.

Integrated Tech Stack Utilizes Salesforce, e-commerce capabilities, and web technologies, enabling scalable digital sales, account management, and direct-to-consumer or B2B2C models. Opportunity to optimize partnerships, onboarding, and remote clinical education programs.

Strategic Partnerships Active participation in VA programs and NHS-like pathways, plus awards recognition, signals a strong alignment with government, veteran, and chronic disease programs. Target government health initiatives, hospital networks, and payer-backed programs to expand adoption.

Neurovalens Tech Stack

Neurovalens uses 8 technology products and services including Complianz, Cloudflare, Cookiebot, and more. Explore Neurovalens's tech stack below.

  • Complianz
    A/B Testing
  • Cloudflare
    Content Management System
  • Cookiebot
    Cookie Compliance
  • Cloudflare DNS
    Domain Name Services
  • Swift
    Programming Languages
  • PHP
    Programming Languages
  • reCAPTCHA
    Security
  • HTTP/3
    Web & Portal Technology

Media & News

Neurovalens's Email Address Formats

Neurovalens uses at least 1 format(s):
Neurovalens Email FormatsExamplePercentage
First.Last@neurovalens.comJohn.Doe@neurovalens.com
93%
Last@neurovalens.comDoe@neurovalens.com
7%

Frequently Asked Questions

What is Neurovalens's official website and social media links?

Minus sign iconPlus sign icon
Neurovalens's official website is neurovalens.com and has social profiles on LinkedInCrunchbase.

How much revenue does Neurovalens generate?

Minus sign iconPlus sign icon
As of August 2026, Neurovalens's annual revenue is estimated to be $1M - $10M.

What is Neurovalens's NAICS code?

Minus sign iconPlus sign icon
Neurovalens's NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does Neurovalens have currently?

Minus sign iconPlus sign icon
As of August 2026, Neurovalens has approximately 31 employees across 2 continents, including EuropeNorth America. Key team members include Ceo: J. M.Chief Technology Officer: C. M.Chief Project Officer: I. H.. Explore Neurovalens's employee directory with LeadIQ.

What industry does Neurovalens belong to?

Minus sign iconPlus sign icon
Neurovalens operates in the Medical Equipment Manufacturing industry.

What technology does Neurovalens use?

Minus sign iconPlus sign icon
Neurovalens's tech stack includes ComplianzCloudflareCookiebotCloudflare DNSSwiftPHPreCAPTCHAHTTP/3.

What is Neurovalens's email format?

Minus sign iconPlus sign icon
Neurovalens's email format typically follows the pattern of First.Last@neurovalens.com. Find more Neurovalens email formats with LeadIQ.

How much funding has Neurovalens raised to date?

Minus sign iconPlus sign icon
As of August 2026, Neurovalens has raised $28M in funding. The last funding round occurred on May 26, 2026 for $6.8M.

When was Neurovalens founded?

Minus sign iconPlus sign icon
Neurovalens was founded in 2013.
Neurovalens logo

Neurovalens

Medical Equipment ManufacturingNorthern Ireland, United Kingdom11-50 Employees

Neurovalens is a Belfast, Northern Ireland-based medical equipment manufacturer and a global health-tech company focused on non-invasive neurostimulation to address significant health challenges. Its Modius platform is FDA-cleared and delivers non-invasive stimulation to deep brain regions, avoiding surgical implants and enabling earlier intervention in treatment pathways. The company is developing multiple versions of the technology, with Modius Sleep as its first product, released in October 2024, and Modius Calm planned for release later. 

Modius Sleep targets chronic insomnia and is a drug-free, physician-prescribed medical device. Worn as a headset for about 30 minutes each evening, the device delivers a safe electrical pulse to influence brain regions that regulate circadian rhythms and sleep, using two pads placed behind the ears.

Section iconCompany Overview

NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Founded
2013
Employees
11-50

Section iconFunding & Financials

  • $28M

    Neurovalens has raised a total of $28M of funding over 12 rounds. Their latest funding round was raised on May 26, 2026 in the amount of $6.8Mas a grant.

  • $1M - $10M

    Neurovalens's revenue is estimated to be in the range of $1M - $10M

Section iconFunding & Financials

  • $28M

    Neurovalens has raised a total of $28M of funding over 12 rounds. Their latest funding round was raised on May 26, 2026 in the amount of $6.8Mas a grant.

  • $1M - $10M

    Neurovalens's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.